Close

Sangamo Therapeutics (SGMO) and Voyager Therapeutics (VYGR) Enter License Deal for Epigenetic Regulation Treatment of Prion Jun 29, 2023 08:05AM
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease Jun 29, 2023 08:05AM
Neurocrine Bio (NBIX), Voyager (VYGR) Enter Pact for Development of Voyager's GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Jan 9, 2023 07:44AM
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurologic Jan 9, 2023 07:00AM
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast Nov 1, 2022 07:30AM
View Older Stories

Oct 18, 2022 04:01PM Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 11, 2022 07:00AM Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
Oct 4, 2022 07:02AM Voyager Therapeutics (VYGR) Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Oct 4, 2022 07:00AM Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Oct 3, 2022 07:00AM Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
Sep 27, 2022 07:00AM Voyager Therapeutics to Participate in Upcoming Investor Conferences
Sep 22, 2022 04:01PM Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2022 07:33AM Voyager Therapeutics (VYGR) Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
Sep 7, 2022 07:30AM Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
Aug 4, 2022 04:01PM Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Aug 3, 2022 11:30AM Voyager Therapeutics (VYGR) Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
Aug 3, 2022 11:30AM Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
Aug 2, 2022 04:01PM Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
Jul 28, 2022 07:00AM Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
May 19, 2022 06:01AM Voyager Therapeutics (VYGR) TRACER Capsids Demonstrate Enhanced CNS Transduction Across Species
May 19, 2022 06:00AM Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
May 16, 2022 06:00AM Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual M
May 4, 2022 04:01PM Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 3, 2022 07:00AM Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
Mar 22, 2022 07:00AM Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
Mar 8, 2022 06:16AM Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Mar 8, 2022 01:15AM Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
Feb 10, 2022 07:00AM Voyager Therapeutics to Participate in Upcoming Investor Conferences
Feb 3, 2022 07:00AM Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
Nov 19, 2021 07:30AM Voyager Therapeutics (VYGR) Reports Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program
Nov 19, 2021 07:30AM Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Nov 16, 2021 07:00AM Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Nov 2, 2021 07:00AM Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
Oct 20, 2021 08:55AM Voyager Therapeutics (VYGR) Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
Oct 20, 2021 08:54AM Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
Oct 6, 2021 07:01AM Voyager Therapeutics (VYGR) Announces License Option Agreement with Pfizer (PFE) for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Oct 6, 2021 07:00AM Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Sep 8, 2021 08:30AM Voyager Digital Partners with Football Star Rob Gronkowski to Expand Crypto Platform & Support Gronk Nation
Sep 2, 2021 05:08PM Voyager Therapeutics to Participate in Upcoming Investor Conferences
Aug 10, 2021 04:20PM Voyager Therapeutics to Participate in Upcoming Investor Conferences
Aug 9, 2021 07:00AM Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
May 19, 2021 04:09PM Voyager Therapeutics (VYGR) Announces Strategic Shift and Leadership Transitions
May 19, 2021 04:01PM Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
May 12, 2021 07:34AM Voyager Therapeutics (VYGR) Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
May 12, 2021 07:30AM Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
May 11, 2021 07:30AM Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
May 10, 2021 07:30AM Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
Apr 28, 2021 08:00AM Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
Apr 26, 2021 08:06AM Voyager Therapeutics (VYGR) Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
Apr 26, 2021 08:00AM Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
Feb 25, 2021 04:01PM Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
Feb 18, 2021 04:01PM Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
Feb 2, 2021 04:02PM Voyager Therapeutics (VYGR) Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Feb 2, 2021 04:01PM Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Jan 25, 2021 09:02AM Usio, Inc (USIO) Enters into Exclusive Contract with Leading Crypto Brokerage - Voyager Digital Holdings
View Older Stories